又一券商“补血”，中泰证券60亿元定增获批

Core Viewpoint - Zhongtai Securities has received approval from the China Securities Regulatory Commission (CSRC) for a private placement of shares amounting to 6 billion yuan, marking a significant step in its capital-raising efforts after a prolonged period of inactivity in equity financing [1][5]. Group 1: Fundraising Details - The company plans to issue up to 2.091 billion shares, which is no more than 30% of its total share capital prior to the issuance [2]. - The controlling shareholder, Zhaomining Group, is set to subscribe for 36.09% of the new shares, amounting to a maximum of 2.166 billion yuan [2]. - The total funds raised will be used to enhance the company's capital base, optimize its business structure, and improve market competitiveness and risk resilience [2][4]. Group 2: Historical Context - The fundraising initiative was first proposed over two years ago, with the initial plan announced on June 30, 2023, marking the company's first equity financing since its listing in 2020 [3]. - The approval process involved multiple extensions and responses to regulatory inquiries, reflecting the complexities of the approval process [3][5]. - The company has not engaged in equity refinancing since its listing, relying instead on non-equity financing methods, which has led to a relatively high debt level and insufficient net capital replenishment [4]. Group 3: Regulatory Approval Process - The CSRC's approval is valid for 12 months from the date of issuance, allowing the company to proceed with the share issuance within this timeframe [1]. - The Shanghai Stock Exchange had previously indicated that the company's application met the necessary conditions for issuance and listing [5].